New Canary Report - Price update to $1.10, page-19

I’m taking a look at the company with a view to maybe buying a few shares aftee a friend recently mentioned BIO again.
That as after him first telling me it was worth a look earlier in the year.
He thought maybe there was more to go - as hypothesised by that Canary report.

nurberg I see you’re a happy holder starting at four and five cents a share since 2019 days - pre IPO?
Congratulations.

What brought you here?
As far as intellectual property in the world of pharma or any other goes - dependency on a supplier may be commonplace but that does not mean it’s not a risk.

cheers